AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17380844
Drug: lercanidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lercanidipine (10 mg/day)
Trial: 17380844
Drug: hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (25 mg/day)
Trial: 13129444
Drug: Tomato lycopene
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato lycopene oleoresin (30 mg/d)
Trial: 10323423
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (2 packages diluted in 2-3 L of water)
Trial: 1902298
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with canned herring (lower dose of n-3 fatty acids)
Trial: 6215008
Drug: Piperacillin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (150 mg/kg/day for urinary tract infections; 250 mg/kg/day for other infections)
Trial: 6215008
Drug: Carbenicillin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenicillin (200 mg/kg/day for urinary tract infections; 450 mg/kg/day for other infections)
Trial: 26018112
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (100 mg daily)
Trial: 25740851
Drug: Matching yeast-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching yeast-based placebo tablets
Trial: 23993469
Drug: Acarbose plus
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose plus metformin fixed-dose combination (FDC)
Trial: 23993469
Drug: Acarbose monotherapy
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose monotherapy
Trial: 20739581
Drug: Levothyroxine (LT4)
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (LT4) suppressive therapy
Trial: 18437288
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of halphaCGRP (2 mug/min)
Trial: 3888863
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg daily
Trial: 10993487
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (200 mg daily)
Trial: 10993487
Drug: d-alpha-tocopherol (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-alpha-tocopherol (700 mg daily)
Trial: 1288514
Drug: Piroxicam +
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam + Ranitidine (300 mg nocte)
Trial: 3885832
Drug: Metoprolol 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 15 mg intravenously followed by 200 mg daily orally
Trial: 29090473
Drug: Quizartinib 40
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib 40 mg/d (DL1; n = 7)
Trial: 29090473
Drug: Quizartinib 60
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib 60 mg/d (DL2; n = 6)
Trial: 23083673
Drug: L paracasei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L paracasei ST11 and B longum BL999 (ST11+BL999)
Trial: 20029223
Drug: Fentanyl transdermal
RxNorm normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patch (FP)
Trial: 20029223
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of local anesthesia (IP)
Trial: 15963867
Drug: Oral extended-release
RxNorm normalized name: Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral extended-release hydromorphone (HHER) administered q24h
Trial: 15963867
Drug: Immediate-release hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release hydromorphone (HHIR) dosed four times daily
Trial: 14673431
Drug: NSAIDs and
RxNorm normalized name: methenamine
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs and supplements
Trial: 14673431
Drug: Chondroprotective supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroprotective supplements
Trial: 10545428
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CE) 0.625 mg/d
Trial: 10545428
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CE and Vitamin E
Trial: 8739514
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist 300 micrograms
Trial: 8739514
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist 600 micrograms
Trial: 2009118
Drug: CPM 4-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPM 4-day group (6 h daily CPM for 4 days in hospital followed by intermittent passive motion at home)
Trial: 2009118
Drug: CPM 14-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPM 14-day group (6 h daily CPM for 14 days)
Trial: 30522739
Drug: Methylphenidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.3 to 0.4 mg/kg (n = 22)
Trial: 26946057
Drug: Tandem high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem high dose chemotherapy with epirubicin, cyclophosphamide, and thiotepa
Trial: 26946057
Drug: Induction with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction with 2× epirubicin-cyclophosphamide followed by tandem HD chemotherapy
Trial: 26946057
Drug: Dose dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose dense chemotherapy (4× epirubicin-cyclophosphamide followed by 3× cyclophosphamide-methotrexate-5-fluorouracil)
Trial: 20460174
Drug: Alternative complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative complex list based randomisation solutions
Trial: 17506136
Drug: VelaSmooth system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VelaSmooth system treatment on one thigh
Trial: 10793229
Drug: Oral casokefamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral casokefamide at doses of 5.5, 8.0, and 16.0 mg
Trial: 10793229
Drug: Oral casokefamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral casokefamide
Trial: 1993412
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Timentin (3.1 g IV at commencement of operation)
Trial: 1993412
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of Timentin (3.1 g IV at commencement of operation and repeated after 2 hours)
Trial: 1993412
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Timentin
Trial: 1993412
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of Timentin
Trial: 30946377
Drug: BiOSS LIM
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BiOSS LIM C stent (dedicated bifurcation balloon expandable stent made of cobalt‐chromium alloy, releasing sirolimus 1.4 μg/mm)
Trial: 30946377
Drug: limus second‐generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: limus second‐generation drug‐eluting stents (DES)
Trial: 30680523
Drug: Aprepitant (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (125 mg on day 1 and 80 mg on days 2-3)
Trial: 26588232
Drug: Fosaprepitant (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant (150 mg, day 1)
Trial: 24823715
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose of 1.0 μg·kg(‐1) dexmedetomidine followed by a continuous infusion of 0.5 μg·kg(‐1) ·h(‐1) (group D1)
Trial: 24823715
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose of 2.0 μg·kg(‐1) dexmedetomidine followed by a continuous infusion of 1.0 μg·kg(‐1) ·h(‐1) (group D2)
Trial: 11779598
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy (850 mg, twice daily)
Trial: 11779598
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate induction (100 mg/day on cycle days 3‐7 of the second cycle) with Metformin
Trial: 11779598
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (twice daily)
Trial: 9828903
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose testosterone treatment (100 mg subcutaneous implants every six months for at least two years, mean duration 3.3 ± 0.9 years)
Trial: 8016878
Drug: OG 37‐325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OG 37‐325 (nva‐cyclosporine, cyclosporine G)
Trial: 2816609
Drug: HLBI monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLBI monotherapy (3 million units daily for 4 days, then twice weekly)
Trial: 2816609
Drug: Combined HLBI
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined HLBI with 5-FU (300 or 600 mg orally)
Trial: 2816609
Drug: Either HLBI
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either HLBI treatment (monotherapy or combined)
Trial: 776840
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CTX, vincristine, and methotrexate - COM)
Trial: 6102627
Drug: Clavulanic acid
RxNorm normalized name: Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clavulanic acid in combination with amoxycillin
Trial: 17593865
Drug: HFA-BDP (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA-BDP (200 microg once daily)
Trial: 17593865
Drug: BUD-TH (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD-TH (400 microg twice daily)
Trial: 17593865
Drug: FP-IH (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP-IH (250 microg twice daily)
Trial: 12374629
Drug: clomipramine+lithium (C+L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clomipramine+lithium (C+L)
Trial: 10357419
Drug: 3D-CRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D-CRT with a minimum tumor dose of 64.8 Gy to 81.0 Gy
Trial: 8596484
Drug: Cephalic-phase insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cephalic-phase insulin response (CPIR) before weight reduction
Trial: 8596484
Drug: Cephalic-phase insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cephalic-phase insulin response (CPIR) after weight reduction
Trial: 8596484
Drug: First-phase insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-phase insulin secretion during intravenous glucose tolerance test (IVGTT)
Trial: 1763606
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta-estradiol
Trial: 6121965
Drug: Methyldopa treatment
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa treatment during pregnancy
Trial: 6794796
Drug: Methyldopa treatment
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa treatment
Trial: 30346340
Drug: Impression Cytology
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Impression Cytology using EYEPRIM device with topical anesthesia
Trial: 30346340
Drug: Impression Cytology
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Impression Cytology using EYEPRIM device without topical anesthesia
Trial: 24945194
Drug: Thalidomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100 mg once daily for 3 months)
Trial: 24945194
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching oral placebo for 3 months)
Trial: 24945194
Drug: Thalidomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100 mg to 200 mg daily for 3 months, open-label follow-up)
Trial: 21052881
Drug: Pregabalin 300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300 mg before surgery and 150 mg every 8 hours
Trial: 21052881
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 550 mg before surgery and 550 mg every 12 hours
Trial: 17107734
Drug: Interferon therapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon therapy (IFN-alpha)
Trial: 2288141
Drug: ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodeoxycholic acid 500 mg once a day
Trial: 31529104
Drug: Nonopioid medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonopioid medication therapy
Trial: 26685082
Drug: Physician-family communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-family communication ratings (answering family's questions, listening to family, asking about treatments patient would want, helping family decide patient's treatment wishes, overall communication)
Trial: 27881132
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 200 μg
Trial: 21828231
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 400 μg
Trial: 21828231
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 600 μg
Trial: 21828231
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 800 μg
Trial: 21828231
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 500 μg
Trial: 18278078
Drug: Cholesterol-lowering medication,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering medication, percutaneous coronary intervention, and coronary artery bypass surgery
Trial: 2258635
Drug: recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant interferon alpha‐2b (rIFN alpha 2b) therapy for a total period of 20 months
Trial: 28408798
Drug: Low-dose SKA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SKA cytokines (IL-4, IL-10, anti-IL-1 antibodies at 10 fg/mL, orally administered at a dose of 20 drops/d for 12 months)
Trial: 28408798
Drug: Disease-modifying antirheumatic
RxNorm normalized name: ANTIRHEUMATICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying antirheumatic drugs (DMARDs) therapy
Trial: 25942722
Drug: NTCD-M3 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTCD-M3 (all doses combined)
Trial: 19127172
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (fluoxetine + cognitive-behavioral therapy)
Trial: 19127172
Drug: Overall (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (all active treatments)
Trial: 18688944
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg)
Trial: 15318251
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (4 ml/kg, 1.8 meq/kg)
Trial: 11289198
Drug: Enhanced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced therapy for early syphilis
Trial: 11289198
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for early syphilis
Trial: 9260006
Drug: Multimodal pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal pain treatment with intrathecal morphine, incisional bupivacaine and ibuprofen+acetaminophen po until hospital discharge (Group 1)
Trial: 9260006
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with iv PCA morphine weaned to acetaminophen+codeine po (Group 2)
Trial: 30861167
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education
Trial: 21933100
Drug: Omalizumab (OMA)
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab (OMA) added to optimized asthma therapy (OAT) for 32 weeks
Trial: 21933100
Drug: Optimized asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimized asthma therapy (OAT) alone for 32 weeks
Trial: 10766183
Drug: GM‐CSF in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF in combination with IL‐4 (0.5‐6.0 microg/kg/day)
Trial: 10766183
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (GM‐CSF and IL‐4)
Trial: 2361891
Drug: Placebo (dextrose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dextrose, 5 mg/kg)
Trial: 22805286
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea polyphenols (GTP) 640 mg
Trial: 19769480
Drug: Menoprogen (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menoprogen (0.2 g extracts of five herbs per capsule, two capsules orally, twice daily)
Trial: 15345867
Drug: Fat-modified diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-modified diet (SFA < 10%, MUFA 10-5%, PUFA up to 10%, cholesterol < 300 mg/day)
Trial: 11393673
Drug: Isradipine 5
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5 mg/day
Trial: 19453311
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron
Trial: 9065130
Drug: Intravenous promethazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous promethazine
Trial: 2680157
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (type 1)
Trial: 2680157
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (type 1)
Trial: 2680157
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (type 2)
Trial: 2680157
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (type 2)
Trial: 2680157
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (lowest ejection fraction tercile)
Trial: 2680157
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (lowest ejection fraction tercile)
Trial: 146916
Drug: Topical retinoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoic acid
Trial: 26046102
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt containing Bifidobacterium lactis (1×10(6) per gram), 200g once daily for 2 weeks
Trial: 19325490
Drug: Rivastigmine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (3 doses of 1.5 mg per day starting the evening before surgery until the evening of the sixth postoperative day)
Trial: 15448038
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of zoledronic acid
Trial: 9069483
Drug: Active warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active warfarin and active aspirin